PDF(Pubmed)
Abstract：
UNASSIGNED: Graves\' disease (GD) is the most common cause of hyperthyroidism, and its pathogenesis remains incompletely elucidated. Numerous studies have implicated the gut microbiota in the development of thyroid disorders. This study employs Mendelian randomization analysis to investigate the characteristics of gut microbiota in GD patients, aiming to offer novel insights into the etiology and treatment of Graves\' disease.
UNASSIGNED: Two-sample Mendelian randomization (MR) analysis was employed to assess the causal relationship between Graves\' disease and the gut microbiota composition. Gut microbiota data were sourced from the international consortium MiBioGen, while Graves\' disease data were obtained from FINNGEN. Eligible single nucleotide polymorphisms (SNPs) were selected as instrumental variables. Multiple analysis methods, including inverse variance-weighted (IVW), MR-Egger regression, weighted median, weighted mode, and MR-RAPS, were utilized. Sensitivity analyses were conducted employing MR-Egger intercept test, Cochran\'s Q test, and leave-one-out analysis as quality control measures.
UNASSIGNED: The Mendelian randomization study conducted in a European population revealed a decreased risk of Graves\' disease associated with Bacteroidaceae (Odds ratio (OR) [95% confidence interval (CI)]: 0.89 [0.89 ~ 0.90], adjusted P value: <0.001), Bacteroides (OR: [95% CI]: 0.555 [0.437 ~ 0.706], adjusted P value: <0.001), and Veillonella (OR [95% CI]: 0.632 [0.492 ~ 0.811], adjusted P value: 0.016). No significant evidence of heterogeneity, or horizontal pleiotropy was detected. Furthermore, the preliminary MR analysis identified 13 bacterial species including Eubacterium brachy group and Family XIII AD3011 group, exhibiting significant associations with Graves\' disease onset, suggesting potential causal effects.
UNASSIGNED: A causal relationship exists between gut microbiota and Graves\' disease. Bacteroidaceae, Bacteroides, and Veillonella emerge as protective factors against Graves\' disease development. Prospective probiotic supplementation may offer a novel avenue for adjunctive treatment in the management of Graves\' disease in the future.
UNASSIGNED: Two-sample Mendelian randomization (MR) analysis was employed to assess the causal relationship between Graves\' disease and the gut microbiota composition. Gut microbiota data were sourced from the international consortium MiBioGen, while Graves\' disease data were obtained from FINNGEN. Eligible single nucleotide polymorphisms (SNPs) were selected as instrumental variables. Multiple analysis methods, including inverse variance-weighted (IVW), MR-Egger regression, weighted median, weighted mode, and MR-RAPS, were utilized. Sensitivity analyses were conducted employing MR-Egger intercept test, Cochran\'s Q test, and leave-one-out analysis as quality control measures.
UNASSIGNED: The Mendelian randomization study conducted in a European population revealed a decreased risk of Graves\' disease associated with Bacteroidaceae (Odds ratio (OR) [95% confidence interval (CI)]: 0.89 [0.89 ~ 0.90], adjusted P value: <0.001), Bacteroides (OR: [95% CI]: 0.555 [0.437 ~ 0.706], adjusted P value: <0.001), and Veillonella (OR [95% CI]: 0.632 [0.492 ~ 0.811], adjusted P value: 0.016). No significant evidence of heterogeneity, or horizontal pleiotropy was detected. Furthermore, the preliminary MR analysis identified 13 bacterial species including Eubacterium brachy group and Family XIII AD3011 group, exhibiting significant associations with Graves\' disease onset, suggesting potential causal effects.
UNASSIGNED: A causal relationship exists between gut microbiota and Graves\' disease. Bacteroidaceae, Bacteroides, and Veillonella emerge as protective factors against Graves\' disease development. Prospective probiotic supplementation may offer a novel avenue for adjunctive treatment in the management of Graves\' disease in the future.
摘要：
■Graves病（GD）是甲状腺功能亢进的最常见原因，其发病机制仍未完全阐明。许多研究表明肠道微生物群与甲状腺疾病的发展有关。本研究采用孟德尔随机化分析来调查GD患者的肠道菌群特征。旨在为Graves病的病因和治疗提供新的见解。
■采用双样本孟德尔随机化（MR）分析来评估Graves病与肠道微生物群组成之间的因果关系。肠道菌群数据来自国际财团MiBioGen，而Graves\'疾病数据是从FINNGEN获得的。选择合格的单核苷酸多态性(SNP)作为工具变量。多种分析方法，包括逆方差加权(IVW)，MR-Egger回归，加权中位数，加权模式，和MR-RAPS,被利用。敏感性分析采用MR-Egger截距试验进行，Cochran的Q测试,和留一法分析作为质量控制措施。
■在欧洲人群中进行的孟德尔随机研究显示，与拟杆菌科相关的格雷夫斯病的风险降低（赔率（OR）[95％置信区间（CI）]：0.89[0.89〜0.90]，调整后的P值：<0.001)，拟杆菌（OR：[95%CI]：0.555[0.437~0.706]，调整后的P值：<0.001)，和Veillonella（OR[95%CI]：0.632[0.492~0.811]，调整后的P值：0.016）。没有明显的异质性证据，或检测到水平多效性。此外，初步MR分析确定了13种细菌，包括肠杆菌组和XIII家族AD3011组，表现出与格雷夫斯病发作显著相关，暗示潜在的因果效应。
■肠道微生物群与Graves病之间存在因果关系。拟杆菌科,拟杆菌,和Veillonella作为对抗Graves病发展的保护因素出现。前瞻性补充益生菌可能为将来治疗Graves病提供一种新的辅助治疗途径。
■采用双样本孟德尔随机化（MR）分析来评估Graves病与肠道微生物群组成之间的因果关系。肠道菌群数据来自国际财团MiBioGen，而Graves\'疾病数据是从FINNGEN获得的。选择合格的单核苷酸多态性(SNP)作为工具变量。多种分析方法，包括逆方差加权(IVW)，MR-Egger回归，加权中位数，加权模式，和MR-RAPS,被利用。敏感性分析采用MR-Egger截距试验进行，Cochran的Q测试,和留一法分析作为质量控制措施。
■在欧洲人群中进行的孟德尔随机研究显示，与拟杆菌科相关的格雷夫斯病的风险降低（赔率（OR）[95％置信区间（CI）]：0.89[0.89〜0.90]，调整后的P值：<0.001)，拟杆菌（OR：[95%CI]：0.555[0.437~0.706]，调整后的P值：<0.001)，和Veillonella（OR[95%CI]：0.632[0.492~0.811]，调整后的P值：0.016）。没有明显的异质性证据，或检测到水平多效性。此外，初步MR分析确定了13种细菌，包括肠杆菌组和XIII家族AD3011组，表现出与格雷夫斯病发作显著相关，暗示潜在的因果效应。
■肠道微生物群与Graves病之间存在因果关系。拟杆菌科,拟杆菌,和Veillonella作为对抗Graves病发展的保护因素出现。前瞻性补充益生菌可能为将来治疗Graves病提供一种新的辅助治疗途径。
